474 related articles for article (PubMed ID: 31371197)
41. REAL-LIFE STUDY IN DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE IMPLANT: The Reldex Study.
Malclès A; Dot C; Voirin N; Agard É; Vié AL; Bellocq D; Denis P; Kodjikian L
Retina; 2017 Apr; 37(4):753-760. PubMed ID: 27471826
[TBL] [Abstract][Full Text] [Related]
42. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema.
Taylor SR; Habot-Wilner Z; Pacheco P; Lightman SL
Ophthalmology; 2009 Apr; 116(4):797-801. PubMed ID: 19344827
[TBL] [Abstract][Full Text] [Related]
43. A Comparison of Ocular Complications after 0.7 mg Dexamethasone Implant versus 2 mg of Intravitreal Triamcinolone in Vitrectomized Eyes.
Wakabayashi T; Liu CK; Anderson HE; Mahmoudzadeh R; Nguyen MK; Salabati M; Chiang A; Hsu J; Garg SJ; Spirn MJ
Ophthalmol Retina; 2023 Jun; 7(6):480-488. PubMed ID: 36572383
[TBL] [Abstract][Full Text] [Related]
44. Rate of hypotony and intraocular pressure fluctuation immediately after intravitreal dexamethasone implantation in vitrectomized eyes.
Alagöz N; Tatar IT; Altan C; Alagöz C; Demir G; Taşkapili M
J Fr Ophtalmol; 2020 Feb; 43(2):103-110. PubMed ID: 31952876
[TBL] [Abstract][Full Text] [Related]
45. A 12-MONTH, SINGLE-MASKED, RANDOMIZED CONTROLLED STUDY OF EYES WITH PERSISTENT DIABETIC MACULAR EDEMA AFTER MULTIPLE ANTI-VEGF INJECTIONS TO ASSESS THE EFFICACY OF THE DEXAMETHASONE-DELAYED DELIVERY SYSTEM AS AN ADJUNCT TO BEVACIZUMAB COMPARED WITH CONTINUED BEVACIZUMAB MONOTHERAPY.
Maturi RK; Bleau L; Saunders J; Mubasher M; Stewart MW
Retina; 2015 Aug; 35(8):1604-14. PubMed ID: 25829346
[TBL] [Abstract][Full Text] [Related]
46. [Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases].
Jonas JB; Kreissig I; Kamppeter B; Degenring RF
Ophthalmologe; 2004 Feb; 101(2):113-20. PubMed ID: 14991306
[TBL] [Abstract][Full Text] [Related]
47. Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant in Korean patients.
Choi W; Park SE; Kang HG; Byeon SH; Kim SS; Koh HJ; Lee S; Seong GJ; Kim CY; Kim M
Br J Ophthalmol; 2019 Oct; 103(10):1380-1387. PubMed ID: 30523044
[TBL] [Abstract][Full Text] [Related]
48. Secondary glaucoma after intravitreal dexamethasone implant (Ozurdex) injection in patients with retinal disorder: A retrospective study.
Sweta VD; Shibi Dev BN; Sandhya R
Indian J Ophthalmol; 2022 Feb; 70(2):585-589. PubMed ID: 35086242
[TBL] [Abstract][Full Text] [Related]
49. COMBINED VITRECTOMY AND INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT.
Zheng A; Chin EK; Almeida DR; Tsang SH; Mahajan VB
Retina; 2016 Nov; 36(11):2087-2092. PubMed ID: 27148836
[TBL] [Abstract][Full Text] [Related]
50. Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema.
Medeiros MD; Alkabes M; Navarro R; Garcia-Arumí J; Mateo C; Corcóstegui B
J Ocul Pharmacol Ther; 2014 Nov; 30(9):709-16. PubMed ID: 25259834
[TBL] [Abstract][Full Text] [Related]
51. SAFETY OF CONSECUTIVE SAME-DAY BILATERAL INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX).
Kapoor KG; Colchao JB
Retin Cases Brief Rep; 2020; 14(2):200-202. PubMed ID: 29155696
[TBL] [Abstract][Full Text] [Related]
52. Two or more dexamethasone intravitreal implants in treatment-naïve patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study.
Dugel PU; Capone A; Singer MA; Dreyer RF; Dodwell DG; Roth DB; Shi R; Walt JG; Scott LC; Hollander DA;
BMC Ophthalmol; 2015 Sep; 15():118. PubMed ID: 26337664
[TBL] [Abstract][Full Text] [Related]
53. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study.
Gillies MC; Lim LL; Campain A; Quin GJ; Salem W; Li J; Goodwin S; Aroney C; McAllister IL; Fraser-Bell S
Ophthalmology; 2014 Dec; 121(12):2473-81. PubMed ID: 25155371
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema.
Guigou S; Pommier S; Meyer F; Hajjar C; Merite PY; Parrat E; Rouhette H; Rebollo O; Matonti F
Ophthalmologica; 2015; 233(3-4):169-75. PubMed ID: 25924737
[TBL] [Abstract][Full Text] [Related]
55. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema.
Cardillo JA; Melo LA; Costa RA; Skaf M; Belfort R; Souza-Filho AA; Farah ME; Kuppermann BD
Ophthalmology; 2005 Sep; 112(9):1557-63. PubMed ID: 16019075
[TBL] [Abstract][Full Text] [Related]
56. Intravitreal Dexamethasone Implant for the Treatment of Postoperative Macular Edema.
Klamann A; Böttcher K; Ackermann P; Geerling G; Schargus M; Guthoff R
Ophthalmologica; 2016; 236(4):181-185. PubMed ID: 27915343
[TBL] [Abstract][Full Text] [Related]
57. PERSISTENT REMNANTS OF DEXAMETHASONE INTRAVITREAL IMPLANT (OZURDEX).
Kim JT; Lee SH; Choi SU
Retina; 2020 Nov; 40(11):2226-2231. PubMed ID: 32058420
[TBL] [Abstract][Full Text] [Related]
58. Intravitreal dexamethasone implant in patients with persistent diabetic macular edema.
Zucchiatti I; Lattanzio R; Querques G; Querques L; Del Turco C; Cascavilla ML; Bandello F
Ophthalmologica; 2012; 228(2):117-22. PubMed ID: 22310491
[TBL] [Abstract][Full Text] [Related]
59. Dexamethasone intravitreal implant (OZURDEX
Massa H; Georgoudis P; Panos GD
Ther Deliv; 2019 Jun; 10(6):343-351. PubMed ID: 31184554
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of dexamethasone intravitreal implant for the treatment of diabetic macular edema.
Bonnin S; Dupas B; Sanharawi ME; Perol J; Erginay A; Tadayoni R; Massin P
Eur J Ophthalmol; 2015; 25(5):448-53. PubMed ID: 25684155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
